Table 3.

Cox PHs (95% CI) for OS and PFS

nsCD163 highPsCD163 continuouslyP
OS 131 3.79 (1.91-7.48) <.001 1.04 (1.02-1.06) <.001 
 131 4.10 (2.06-8.16) <.001 1.04 (1.02-1.06) <.001 
 57 4.33 (1.32-14.2) .016 1.04 (0.996-1.08) .075 
PFS 131 2.73 (1.16-4.62) <.001 1.04 (1.02-1.05) <.001 
 131 3.13 (1.83-5.36) <.001 1.04 (1.02-1.05) <.001 
 57 3.48 (1.42-8.54) .006 1.04 (1.003-1.07) .034 
nsCD163 highPsCD163 continuouslyP
OS 131 3.79 (1.91-7.48) <.001 1.04 (1.02-1.06) <.001 
 131 4.10 (2.06-8.16) <.001 1.04 (1.02-1.06) <.001 
 57 4.33 (1.32-14.2) .016 1.04 (0.996-1.08) .075 
PFS 131 2.73 (1.16-4.62) <.001 1.04 (1.02-1.05) <.001 
 131 3.13 (1.83-5.36) <.001 1.04 (1.02-1.05) <.001 
 57 3.48 (1.42-8.54) .006 1.04 (1.003-1.07) .034 

The prognostic value of sCD163 is shown dichotomized at median level of sCD163 (3112 ng/mL) and as a continuous variable at intervals of 100 ng/mL. The model is stratified by time of sampling (at diagnosis or at relapse) and adjusted for: (a) univariable (b) age ≥ 70 years, sex. (c) MIPI, Ki-67 ≥30%, blastoid histology and presence of p53 overexpression or TP53 mutation. Model (c) is based on the population-based cohort from Uppsala and the clinical study cohort.

Boldface indicates statistically significant values.

MIPI, mantle cell lymphoma international prognostic index.

Close Modal

or Create an Account

Close Modal
Close Modal